1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO18109, NCT00949910
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HFHS 05-03, NCT00448240
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: IFCT-0801, Eudract : 2008-004939-38, NCT00775385
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GERCOR-C04-2, EU-20565, GERCOR-OPTIMOX3-TARCEVA, ROCHE-GERCOR-C04-2, NCT00265824, GERCOR-DREAM- C04-2
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TASMC-05-FB-05235-CTIL, NCT00268684
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 75 to 90
Sponsor: Other
Protocol IDs: IFCT-0501, NCT00298415
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2005.386, NCT00300586
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-774-302, NCT00373425
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML20294, NCT00412217
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: CT/06.05, NCT00440414
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EURTAC-SLCG // GECP06/01, EudraCT:2006-003568-73, NCT00446225
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181087, SUN1087, NCT00457392
|
|
13.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2003-0824, EPOC, NCT00402779
|
|
14.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO18602, NCT00556322
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ML19033, EUDRACT 2006-002295-18, NCT00598156
|
|
16.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GERCOR-LAP-07-D07-1, GERCOR-LAP-07-D07-1, EU=20827, ROCHE-GERCOR-LAP-07-D07-1, EudraCT- 2007-001174-81, NCT00634725
|
|
17.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FARM6F5JER, EudraCT Number 2007-004786-17, NCT00637910
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021018, NCT00673049
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: Shixiu - 1, NCT00686114
|
|
20.
|
Phase: Phase III
Type: Prevention, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: KROG-4-2008-0276, 4-2008-0276, NCT00955695
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ML20981, NCT00874419
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22201, NCT00883779
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12917, EudraCT:2008-006021-14, SEARCH, NCT00901901
|
|
24.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SRSI-HSRL-02-2007, HSRL-02-2007, PROSE, 2007-006299-13, EU-20975, NCT00989690
|
|
25.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0848, RTOG 0848, NCT01013649
|
